Company Encyclopedia
View More
name
LENZ Therapeutics
LENZ.US
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc.
4.599 T
LENZ.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking75/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-28.78%E
    • Profit Margin-336.47%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY3.17%C
    • Total Assets YoY-5.94%D
    • Net Assets YoY-9.92%D
  • Cash ScoreD
    • Cash Flow Margin-29.72%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.08E
  • Debt ScoreA
    • Gearing Ratio7.96%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Top 10 US Stock Losers (12.12)

    Fermi(FRMI) fell 33.84%, with a trading turnover 602.5 Million USD, and a year-to-date fell 52%. LENZ Therapeutics(LENZ) fell 25.96%, with a trading turnover 123.8 Million USD, and a year-to-date fell 37.2%. Modine Manufacturing(MOD) fell 15.32%, with a trading turnover 324.8 Million USD, and a year-to-date rose 20.7%.

    Top Gainers & Losers·
    US
    FRMI
    -33.84%
    US
    LENZ
    -25.96%
    US
    MOD
    -15.32%
    Top Gainers & Losers·
    US
    FRMI
    -33.84%
    US
    LENZ
    -25.96%
    US
    MOD
    -15.32%

    LENZ Therapeutics' Partner Lotus Pharma Seeks Approval For VIZZ To Treat Presbyopia In South Korea

    LENZ Therapeutics' partner Lotus Pharmaceutical has submitted a New Drug Application to South Korea's Ministry of Food and Drug Safety for VIZZ, a treatment for presbyopia. The submission is based on positive Phase 3 trial data. LENZ is set to receive up to $125 million in milestone payments and royalties under a 2025 agreement. VIZZ was approved in the U.S. in July.

    rttnews·
    US
    LENZ
    -25.96%
    rttnews·
    US
    LENZ
    -25.96%

    Lenz Therapeutics, Lotus Pharmaceutical Say New Drug Application for Presbyopia Treatment Submitted in South Korea

    Lenz Therapeutics and Lotus Pharmaceutical have submitted a new drug application for Vizz, a presbyopia treatment, to South Korea's Ministry of Food and Drug Safety. The application is backed by successful phase 3 trial data from the US. Lenz Therapeutics may receive up to $125 million in milestone payments and royalties. Lenz's shares fell over 1%, trading at $29.72.

    fidelity·
    US
    LENZ
    -25.96%
    fidelity·
    US
    LENZ
    -25.96%

    enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia

    Lotus Pharmaceutical Co Ltd :LENZ THERAPEUTICS ANNOUNCES MFDS SUBMISSION OF NEW DRUG APPLICATION FOR LNZ100 (VIZZ™) IN SOUTH KOREA FOR THE TREATMENT OF PRESBYOPIA

    Reuters·
    US
    LENZ
    -25.96%
    Reuters·
    US
    LENZ
    -25.96%

    Lenz Therapeutics Announces Licensing Agreement Milestone With Lotus for VIZZ in South Korea and Southeast Asia

    Lenz Therapeutics announced a milestone in its licensing agreement with Lotus Pharmaceutical, as Lotus submitted a New Drug Application for VIZZ in South Korea. The agreement, signed in May 2025, covers South Korea and Southeast Asia, with Lenz eligible for up to $125 million in milestone payments and royalties. Lotus holds exclusive rights for VIZZ's development and commercialization in these regions.

    Reuters·
    US
    LENZ
    -25.96%
    Reuters·
    US
    LENZ
    -25.96%
    © 2025 Longbridge｜Disclaimer